Patient Outcomes After Resection of Pigmented Villonodular Synovitis in Patients in King Abdulaziz Medical City.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

Conflict of interest statement: Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. 5. Knee. 2025 Oct;56:407-414. doi: 10.1016/j.knee.2025.06.006. Epub 2025 Jul 5. Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom. Ward TRW(1), Ashford RU(2), Eastley NC(2). Author information: (1)University Hospitals of Leicester NHS Trust, United Kingdom. Electronic address: Thomasrwward@doctors.org.uk. (2)University Hospitals of Leicester NHS Trust, United Kingdom; East Midlands Sarcoma Service, United Kingdom; The University of Leicester, United Kingdom. BACKGROUND: Tenosynovial Giant Cell Tumours (TGCTs) are a group of rare, benign, mesenchymal tumours involving synovium, bursae or tendon sheaths. There are two subtypes of TGCT (nodular (nTGCT) and diffuse (dTGCT)) and the current guidelines on the management of both is limited. METHODS: A questionnaire was distributed to members of the British Orthopaedic Oncology Society to investigate members' management of primary and recurrent TGCT. Respondents were questioned on their chosen radiological investigations, use of biopsy, surgical and oncological management and follow up. Descriptive analysis of the qualitative data was performed through data coding. RESULTS: Eighteen responses were received from orthopaedic consultants subspecialising in sarcoma surgery. One was excluded due to practice outside of the United Kingdom (UK). Magnetic Resonance Imaging (MRI) was unanimously the primary investigation of choice. Biopsy rates varied depending on extent of disease, imaging appearances and MDT input. Most surgeons manage primary and recurrent nodular and diffuse TGCT with an open excision. When surgery is performed by a knee or soft-tissue knee surgeon, excisions were more likely to be performed arthroscopically. A staged resection was most commonly performed for dTGCT. Indications for additional therapies in dTGCT varied between units. Follow up regimens also varied, although unsurprisingly diffuse and recurrent disease were reviewed with increased frequency for a longer duration. DISCUSSION: TGCT is a rare, complex disease that encompasses a range of phenotypes. Despite a recent global consensus meeting, our data shows that TGCT is still investigated, managed, and followed up with great variability across the UK. Copyright © 2025 Elsevier B.V. All rights reserved. DOI: 10.1016/j.knee.2025.06.006